Journal
THORACIC CANCER
Volume 13, Issue 4, Pages 549-556Publisher
WILEY
DOI: 10.1111/1759-7714.14294
Keywords
exacerbation; interstitial lung disease; non-small cell lung cancer; prognosis; sarcopenia
Categories
Funding
- [TS2020-0207]
Ask authors/readers for more resources
The study found that sarcopenia can predict chemotherapy-triggered ILD exacerbation and overall survival in patients with ILD-complicated NSCLC, with higher exacerbation rates and shorter survival observed in the sarcopenia group. This suggests the potential value of sarcopenia in guiding treatment approaches.
Background While recent evidence has suggested that sarcopenia could predict chemotoxicity, its association with chemotherapy-triggered interstitial lung disease (ILD) exacerbations has yet to be investigated. Thus, the present study sought to determine whether sarcopenia could predict ILD exacerbations and overall survival (OS) in patients with ILD-complicated non-small cell lung cancer (NSCLC). Methods From January 2010 to July 2020, 74 patients with ILD-complicated NSCLC who received chemotherapy were retrospectively investigated. After categorizing patients according to the presence or absence of sarcopenia based on the psoas muscle index, ILD exacerbation rates and OS were evaluated. Results Among the patients in the study, 39 were included in the sarcopenia group. Moreover, 17 (22.9%) patients developed ILD exacerbations, with the sarcopenia and nonsarcopenia groups having an exacerbation rate of 33.3% and 11.4%, respectively (p = 0.025). Multivariate analysis identified sarcopenia as an independent predictor of ILD exacerbations (p = 0.039). Furthermore, patients with sarcopenia demonstrated a significantly shorter median OS compared to those without the same (9.2 vs. 13.3 months; p = 0.029). Conclusions Sarcopenia predicted chemotherapy-triggered ILD exacerbation and OS in patients with ILD-complicated NSCLC, suggesting its utility in determining treatment approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available